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CCL2 upregulation triggers hypoxic
preconditioning-induced protection from stroke
Ann M Stowe3, Bradley K Wacker1, Petra D Cravens3, Jennifer L Perfater1, Min K Li3, Ruilong Hu1, Angela B Freie1,
Olaf Stüve3,4 and Jeffrey M Gidday1,2*

Abstract
Background: A brief exposure to systemic hypoxia (i.e., hypoxic preconditioning; HPC) prior to transient middle
cerebral artery occlusion (tMCAo) reduces infarct volume, blood-brain barrier disruption, and leukocyte migration.
CCL2 (MCP-1), typically regarded as a leukocyte-derived pro-inflammatory chemokine, can also be directly
upregulated by hypoxia-induced transcription. We hypothesized that such a hypoxia-induced upregulation of CCL2
is required for HPC-induced ischemic tolerance.
Methods: Adult male SW/ND4, CCL2-null, and wild-type mice were used in these studies. Cortical CCL2/CCR2
message, protein, and cell-type specific immunoreactivity were determined following HPC (4 h, 8% O2) or room air
control (21% O2) from 6 h through 2 weeks following HPC. Circulating leukocyte subsets were determined by
multi-parameter flow cytometry in naïve mice and 12 h after HPC. CCL2-null and wild-type mice were exposed to
HPC 2 days prior to tMCAo, with immunoneutralization of CCL2 during HPC achieved by a monoclonal CCL2
antibody.
Results: Cortical CCL2 mRNA and protein expression peaked at 12 h after HPC (both p < 0.01), predominantly in
cortical neurons, and returned to baseline by 2 days. A delayed cerebral endothelial CCL2 message expression (p <
0.05) occurred 2 days after HPC. The levels of circulating monocytes (p < 0.0001), T lymphocytes (p < 0.0001), and
granulocytes were decreased 12 h after HPC, and those of B lymphocytes were increased (p < 0.0001), but the
magnitude of these respective changes did not differ between wild-type and CCL2-null mice. HPC did decrease
the number of circulating CCR2+ monocytes (p < 0.0001) in a CCL2-dependent manner, but immunohistochemical
analyses at this 12 h timepoint indicated that this leukocyte subpopulation did not move into the CNS. While HPC
reduced infarct volumes by 27% (p < 0.01) in wild-type mice, CCL2-null mice subjected to tMCAo were not
protected by HPC. Moreover, administration of a CCL2 immunoneutralizing antibody prior to HPC completely
blocked (p < 0.0001 vs. HPC-treated mice) the development of ischemic tolerance.
Conclusions: The early expression of CCL2 in neurons, the delayed expression of CCL2 in cerebral endothelial cells,
and CCL2-mediated actions on circulating CCR2+ monocytes, appear to be required to establish ischemic tolerance
to focal stroke in response to HPC, and thus represent a novel role for this chemokine in endogenous
neurovascular protection.

Background
Preconditioning occurs when an organism, tissue, or cell
is exposed to a stressful, but non-damaging, stimulus
that initiates genomic reprogramming for protection
from subsequent injury [1-3]. One well-established
model to induce “ischemic tolerance” in the central
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nervous system (CNS) utilizes a brief exposure to systemic hypoxia as the preconditioning stimulus (hypoxic
preconditioning; HPC) to promote neurovascular protection in stroke [4-7]. Mechanistically, hypoxia activates
survival-promoting signaling pathways responsible for
altering gene expression via the upregulation of
hypoxia-inducible factor-1 (HIF-1) [8]. HIF-1 modifies
the expression of effector pathways that ultimately come
to define the ischemia-tolerant phenotype, in part
through the specific upregulation of HIF-1 in cortical
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neurons [8]. Following ischemia, HIF-1 mediated
mechanisms contribute to cortical repair via the homing
of progenitor cells to the site of injury [9], the upregulation of pro-angiogenic molecules [10,11], and the upregulation of erythropoietin [10,12].
CCL2, or monocyte chemoattractant protein (MCP)-1,
is one of only two chemokines under the direct transcriptional control of HIF-1a regulation [13]. CCL2 is
predominantly produced by astrocytes and resident
microglia, and is traditionally known for its role in
recruiting neutrophils and macrophages [14], as well as
circulating neuroblasts [15], to sites of cortical injury
under multiple pathological states. CCL2 is a full competitive agonist to its receptor, CCR2 [11], a Gaicoupled receptor that modulates its signaling based on
binding to individual CC-motif chemokines [12]. CCR2
is found on virtually all CNS cell types, including neurons, glial, endothelial, and immune cells [13-16], and is
the only known receptor for CCL2 - although CCR2
also binds the chemokines CCL7, CCL8, CCL13, and
CCL16 [16]. Several studies suggest a detrimental role
for CCL2 in the progression of stroke injury, as both
CCL2-/- [17] and CCR2-/- [18] mice exhibit reduced
infarct volumes compared to wild-type controls.
Given its well-documented pro-inflammatory roles,
CCL2 seems an unlikely candidate for inducing neuroprotection. However, since it is well established that
harmful stimuli at higher doses can - at lower doses serve as preconditioning stimuli, a role for chemokines
in general, and CCL2 in particular, in the induction of
ischemic tolerance is not necessarily unexpected. Indeed,
several traditionally pro-inflammatory stimuli, including
lipopolysaccharide (LPS) [18,19], tumor necrosis factora (TNF-a) [20], and even brief ischemia [21], upregulate
signaling pathways that induce stroke tolerance. Evidence for the contribution of CCL2 to upstream cellular
signaling during injury and repair shows that CCL2CCR2 signaling upregulates transcription factors, including MCP-1-induced protein (MCPIP) [19] and Ets-1
[20], in monocytes and endothelial cells to initiate
angiogenesis, a process that is critical to stroke recovery
[21]. In addition, overexpression of CCL2 in cardiac
myocytes protects during myocardial ischemia by activation of SAPK/JNK1/2 pathway [22], although, by implication, the activity of other signal transduction pathways
downstream of CCR2 receptor activation (e.g., MAPK,
ERK, and phospholipase C) may also participate in this
epigenetic response [15,23,24].
Because of the direct upregulation of CCL2 by hypoxia
and these signaling intermediary roles, we investigated
whether CCL2 participates as a mediator of HPCinduced tolerance to stroke. We found that a single
exposure to systemic hypoxia (our HPC stimulus)
rapidly upregulates CCL2 mRNA and protein early in
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cortical neurons, with a delayed upregulation of CCL2
message in cortical microvessels. In the periphery, HPC
reduced circulating granulocyte, T lymphocyte, and
monocyte populations, while increasing B lymphocytes,
in a CCL2-independent manner. However, CCL2 regulated the transmigration of CCR2+ monocytes out of the
peripheral blood in response to HPC. Moreover, in mice
that lack bioavailable CCL2, either through genetic
knockout or immunoneutralization, ischemic tolerance
to HPC was not achieved, providing causal evidence for
CCL2, likely produced by both neurons, cerebral
endothelial cells, and circulating leukocytes, as a proximal signaling factor in HPC-induced gene induction
pathways. While the fundamental mechanisms of CNS
preconditioning have been under investigation for a
couple of decades, this is the first evidence of chemokine signaling being critical to the induction of ischemic
tolerance.

Methods
Hypoxic preconditioning (HPC)

The respective Institutional Animal Care and Use Committees at Washington University School of Medicine
and University of Texas, Southwestern Medical Center
approved all experimental procedures. Some experiments (i.e., those for CCL2 message and protein quantification, and immunohistochemistry) were carried out
using SW/ND4 mice (Harlan Bioproducts) to match
previously published results [5]. With the identification
of CCL2 message and protein upregulation after HPC,
remaining studies designed to assess causality were carried out in CCL2-/-/CX3 CR1GFP/+ mice on a C57BL/6
background (courtesy of Dr. Keiko Hirose, Washington
University), with CCL2+/+/CX3CR1GFP/+ and C57BL/6
wild-type controls. CX3CR1GFP/+ mice have one functioning copy of the fractalkine receptor, CX 3 CR1, on
monocytes, macrophages, and some dendritic/NK cells,
which also fluoresce green. All studies used adult male
mice, 25-35 g and 9-12 week old, randomized to experimental groups. Mice were preconditioned in modified
home cages, with food and water available, and normobaric 8% O2 supplied continuously (1.5 L/min) for 4 h
[5]. Outflow air was monitored via an oxygen analyzer
(Vascular Technologies) to confirm the degree of ambient hypoxia. Naïve/control animals had no exposure to
hypoxia.
Quantitative rt-PCR

Animals were sacrificed 6 h through 2 week following
hypoxic preconditioning (HPC). Following isoflurane
overdose, animals were transcardially perfused with 20
mL 0.01 M PBS with heparin (1,000 units/mL) in
RNAse-free sterile water. The neocortex was removed,
and total RNA was isolated from cortical homogenates
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using standard techniques [25]. In the remaining hemisphere, a microvessel fraction (including largely capillaries, but also some small arterioles and venules) was
isolated by differential centrifugation in sucrose buffer
[5]. Primers (Integrated DNA Technologies, Coralville,
IA) for CCL2 and CCR2 were normalized against copies
of the housekeeping gene ribosomal 18S during quantitative real-time PCR (qPCR).
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Minneapolis, MN). Isotype-matched monoclonal antibodies were used to determine non-specific binding. Red
blood cells were lysed using FACsLyse (BD Biosciences)
according to the manufacturer’s directions. Cells were
immediately collected on the FACSAria (BD Biosciences) equipped with Diva Software. Data were analyzed using Flowjo software (Treestar, Ashland, OR).
Transient focal cerebral ischemia

Cerebral whole cell lysate immunoblotting

Animals were sacrificed as stated above for qPCR.
Whole cell homogenates of perfused neocortices in lysis
buffer were immunoblotted using standard protocols
[7]. 85 μg of protein/well was loaded (10-20% gel; BioRad, Hercules, CA), blocked, and incubated overnight in
primary antibody solution (1:1000, CCL2 (Abcam, Cambridge, MA); 1:1000, CCR2 (Novus, Littleton, CO);
1:40,000, b-actin). Secondary antibodies (1:10,000; LiCor,
Lincoln, NE) were image captured using the Li-Cor
Odyssey Infrared Imaging System.
Confocal immunofluorescent histochemistry

Animals were sacrificed 6 h through 2 week following
HPC, at times corresponding to the quantitative rt-PCR
analysis. Mice were transcardially perfused (20 mL 0.01
M PBS, 40 mL 4% paraformaldehyde/0.01 M PBS), brains
cryoprotected in 30% sucrose, and sectioned at 10 μm in
the coronal plane. Representative sections from the MCA
territory were blocked and stained using standard procedures [5,25]. Primary antibodies detected CCL2 (1:20;
PeproTech, Rocky Hill, NJ), neurons (NeuN 1:100; Millipore, Billerica, MA), astrocytes (GFAP 1:200; Molecular
Probes, Grand Island, NY), or endothelial cells (CD31
1:50; BD Pharmingen, Franklin Lakes, NJ), followed by
secondary antibodies (Alexa Fluor 488, 568, 598; 1:300;
Invitrogen, Grand Island, NY) and counterstain (ToPro3;
1:300; Invitrogen). All photomicrograph images were
obtained using an Olympus (Center Valley, PA) Fluoview
(FV1000) confocal laser-scanning microscope or a Nanozoomer 2.0 (Hamamatsu, Bridgewater, NJ).
Whole blood staining for flow cytometry

Blood was collected into EDTA-containing microtubes
and stained to identify circulating leukocytes. After
blocking Fc receptors with anti-CD16/CD32 (BD Biosciences, Billerica, MA), whole blood was stained with
the following titrated antibodies (Ab): anti-CD45 APC
to identify hematopoietic cells; anti-TCRb PE-Cy5 to
identify T lymphocytes; anti-CD4 PE-Texas Red to identify lymphocyte subsets; anti-Gr1 APC-Cy7 (BD Biosciences) to identify granulocytes and monocytes; antiCD19 Alexa Fluor 700 to identify B lymphocytes; antiCD11b Pacific Blue to identify monocytes (eBioscience,
San Diego, CA); and anti-CCR2-PE (R&D Systems,

Mice were anesthetized using a brief exposure to 4%
isoflurane/70% NO2/30% O2, with 1.8% isoflurane as a
maintenance dose for the remainder of the procedure,
as detailed previously [4,26,27]. In all mice, laser Doppler flowmetry (LDF; TSI, Inc., Shoreview, MN) measured relative change in cortical blood flow. Briefly,
following topical preparation of the scalp, an incision at
the temporal muscle exposed the left middle cerebral
artery (MCA) territory, and the probe tip was targeted
to the MCA territory based on anatomical landmarks.
For transient middle cerebral artery occlusion (tMCAo),
a ventral midline incision on the neck exposed the left
common carotid artery, which was permanently ligated
proximal to the suture placement. A silicon-coated, 6.0gauge, nylon suture, 12 mm in length, was advanced
9.0-10.5 mm to transiently block the origin of the MCA,
and confirmed with a second LDF reading, with > 80%
reduction in relative blood flow to baseline required for
inclusion. Body temperature was maintained at 37°C
throughout the surgical procedure; animals were placed
in a heated incubator (34°C) during ischemia. After
either 35 or 45 min, animals were re-anesthetized, continued occlusion of the MCA confirmed by LDF, and
the suture withdrawn. Successful reperfusion of the
MCA territory was defined as a return of cortical blood
flow > 50% of baseline at 10 min. Animals not meeting
the above criteria were removed from the study.
Infarct quantification

Animals were sacrificed 24 h following tMCAo by isoflurane overdose, then transcardially perfused with 20
mL heparinized saline. Upon removal of brains and
gross examination, animals that underwent subarachnoid hemorrhage at the Circle of Willis, secondary to
suture placement, were excluded from further analysis.
Brains were sectioned on a 1.5-mm thick brain matrix
and exposed to 2,3,5-triphenyl tetrazolium chloride
(TTC) to delineate infarct regions. Infarct volumes were
quantified by a blinded observer using standard image
analysis software and corrected for edema based on corresponding right hemispheric areas as control [4,27].
CCL2 immunoneutralization

Either control rat IgG IIb, or monoclonal CCL2 antibody (both from R&D Systems, Minneapolis, MN), were
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administered (2 mg/kg in sterile PBS, i.p.) 3 h before
HPC [28].
Statistical analyses

Data are presented as mean ± standard error of the
mean (SEM), and the necessary group size confirmed by
power analysis. Statistical comparisons were evaluated
using student’s t-test or one-way ANOVA, with Bonferroni post-hoc analysis (Prism, GraphPad, LaJolla, CA),
for all experiments except the neurologic deficit scores,
which were evaluated using Mann-Whitney rank sum
test. Outliers outside the 95% confidence interval were
excluded from final analysis, but are shown as open circles in the figures. Significance was determined as p <
0.05.

Results and discussion
Hypoxic preconditioning upregulates an early CCL2
response within the CNS

It is now appreciated that hypoxia stabilizes the alpha
subunit of HIF-1, allowing it to dimerize to the beta
subunit, translocate, and transcribe a host of both injurious and pro-survival genes in hypoxic cells, the relative
expression of which depends on the severity and duration of hypoxic stimulus [29]. CCL2 contains a HIF-1
binding motif within its promoter region [13], and in
vitro studies confirm hypoxia’s ability to upregulate
CCL2 in a HIF-1-dependent manner [13,30]. While in
vivo systemic hypoxic exposure rapidly upregulates
CCL2 expression in the periphery [31,32], whether brief
hypoxia affects CCL2 within the CNS in a similar way
was not known prior to our investigation. We therefore
quantified CCL2 mRNA expression in hemispheric cortical homogenates from mice exposed to HPC 6 h
through 2 week earlier (n = 7-8/group). Six hours after
HPC, cortical CCL2 mRNA expression was increased 3fold over naïve, and peaked at 11-fold over naïve 12 h
after HPC (p < 0.01; Figure 1A). The elevation in cortical CCL2 message was fading by 24 h and was not distinguishable from baseline 2 days or 2 week after HPC.
Our immunoblot analyses confirmed that cortical CCL2
protein expression also peaked at 12 h, with a 1.6-fold
increase (p < 0.01) over naïve levels, and returned to
baseline by 2 days following HPC (n = 4-7/group; Figure
1B). The expression change we observed, with a 12-h
peak in CCL2 protein levels, was earlier than that occurring after permanent focal stroke [33], which suggests a
potentially unique role for CCL2 following a mild, noninjurious hypoxic stimulus relative to its actions following complete ischemia. Since CCL2 is best known as a
chemoattractant for monocytes/macrophages [15], we
isolated microvessels from the remaining hemisphere of

Figure 1 Unique temporal profiles of hypoxic preconditioning
induced upregulation of CCL2 message and protein in brain.
HPC (4 h, 8%O2) induces an early (A) 11-fold increase in cortical
CCL2 mRNA and (B) 1.5-fold increase in CCL2 protein in cortical
whole cell lysates, as well as a delayed (C) 3.5-fold increase in CCL2
mRNA expression in cortical endothelial cells (black bars) relative to
naïve animals. CCR2 message and protein (grey bars) did not
significantly change relative to naïve expression in cortical
homogenates (A, B), but did in endothelial homogenates (C) within
the same animals at 24 h after HPC. *p < 0.05 vs. respective
expression level in naïves.
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the same animals to quantify CCL2 mRNA expression
in cerebral endothelium (Figure 1C). We found HPCinduced changes in cerebral endothelial cell CCL2
expression, but not temporally parallel with that we
observed in cortical homogenates. Specifically, no
changes in expression occurred between 6 h and 24 h
after HPC, but a large 3.5-fold increase (p < 0.05) in
expression was evidenced in the microvessel fraction 2
days after HPC. By 2 week post-HPC, expression levels
were back to baseline. CCL2 expression within the vasculature is required for CCR2+ monocyte rolling, adherence, and extravasation from blood into tissue beds
[34,35]. Thus, this may reflect one aspect of the ‘effector
phenotype’ established by the prior HPC stimulus,
wherein the recruitment of monocytes to the brain
could be enhanced at times more coincident with stroke
onset (2 d), and not during the time of peak CCL2
expression (6-12 h), when CCL2 acts as a proximal signaling mediator for inducing adaptive responses in resident brain cells to protect them from a future ischemic
event.
Ischemic injury in vivo upregulates CCL2 in several
CNS cell types, including neurons [36,37], astrocytes
[30,33,38,39], macrophages/microglia [33,39], and
endothelial cells [37]. Because our qPCR analysis of the
cortical microvascular fraction showed no upregulation
of CCL2 message at 12 and 24 h after HPC, but our
mRNA and protein measures in cortical homogenates
revealed increased CCL2 expression at these times, we
used a immunohistochemical approach to determine
which remaining cell type contributed to the HPCinduced response. Figure 2 shows a temporal immunohistochemical analysis of HPC-induced CCL2 protein
expression in the cortex, and our neuronal, astrocyte,
and endothelial cell colocalization results. As with our
qPCR and immunoblot findings, the strongest CCL2
immunoreactivity occurred 12 h and 24 h following
HPC, and neurons were the predominant cell type
expressing this chemokine. Regions with reactive,
GFAP-positive astrocytes were rare, but typically found
in cortical layer V/VI, near the corpus callosum, if present; nevertheless, there was minimal astrocyte expression of CCL2 in these regions during these times. A
very small number of macrophages were also identified
in the cortex at 6 h after HPC, and all of these colocalized with CCL2 (data not shown). Taken together, our
results indicate that HPC induces a relatively rapid and
highly neuron-specific upregulation of CCL2 within
hours of the hypoxic exposure, and a delayed upregulation in cerebral endothelium two days after hypoxia,
which suggested to us the hypothesis that this chemokine may contribute to the induction of the genomic
reprogramming underpinning the ischemia-tolerant phenotype. Moreover, the finding of inactivation of HIF-1
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transcription in neurons in vitro increases hypoxiainduced cell death, whereas the inactivation of HIF-1 in
astrocytes in co-cultures is neuroprotective [40], is also
consonant with our hypothesis that a brief, neuron-specific upregulation of CCL2, and perhaps other HIF-1
target genes, ultimately promote the ischemia-resistant
phenotype.
At no time after HPC was the cortical expression of
the CCL2 receptor, CCR2, significantly affected,
although there were trends for both CCR2 mRNA (p =
0.06) and protein (p = 0.10) expression increases over
naïve levels at 12 h following HPC (Figure 1A, B). In
addition, there was no discernable qualitative difference
in cortical CCR2 immunohistochemical expression following HPC (data not shown). There was a brief transient upregulation of endothelial CCR2 mRNA (p < 0.05)
at 24 h after HPC that preceded the endothelial upregulation of CCL2 mRNA at 2 days. However, this response
was not identified immunohistochemically at the protein
level (Figure 1C). Although others have shown that, at
least in monocytes, CCR2 message is downregulated following in vitro hypoxia [41], our in vivo findings indicate that HPC upregulates CCR2 within at least two
resident brain cells, each along a distinct timeline. Even
without a concomitant upregulation in CCR2 expression, the HPC-induced early upregulation in CCL2 production by neurons, and later in microvessels, is likely
to have functional consequences, and implies CCL2mediated autocrine/paracrine signaling is critical to the
induction of ischemic tolerance.
Hypoxic preconditioning alters circulating monocyte,
granulocyte, and lymphocyte populations, but
independent of CCL2

Given that HPC is a systemic stimulus, hypoxia-induced
changes in CCL2 expression in the periphery - particularly in circulating immune cells - may also contribute
to the establishment of the ischemia-tolerant phenotype.
We therefore examined whether HPC affected circulating white blood cell populations, and whether CCL2
modulates this response. Figure 3A shows the frequency
of leukocyte subsets in whole blood, based on a CD45+
gating [42], in both wild-type CX3CR1GFP/+ and CCL2null mice, under naïve conditions, and 12 h after HPC,
the time when peak CCL2 protein expression occurred
within the CNS. Under resting conditions, the genetic
deletion of CCL2 (n = 7) resulted in higher basal levels
of Gr1+ granulocytes (26% increase) and B lymphocytes
(28% increase) compared to wild-type CX 3 CR1 GFP/+
mice (n = 5), although the increases in each subpopulation were not statistically significant. TCRb+ T lymphocytes were similarly elevated in CCL2-null mice (28%
over wild-type), and this increase was significant (p <
0.0001). In contrast, CD11b + monocytes were
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Figure 2 CCL2 protein expression in brain after HPC. (A) Temporal immunohistochemical analyses for CCL2 protein shows an early
colocalization (at 6, 12, and 24 h) of CCL2 protein (red; middle panel) with NeuN-positive neurons (green; left panel) in the cortical grey matter
after HPC (4 h, 8%O2). CCL2 reactivity was minimal in naïve animals and again at 2 days and 2 week after HPC. (B and C) Additional
immunolabeling confirmed that CCL2 protein did not colocalize with (B) CD31-positive cortical endothelial cells (green; left panel), or with (C)
GFAP-positive reactive astrocytes (green; left panel) within 24 h of HPC. ToPro3 (blue; right panel) was used in all photomicrographs as a general
nuclear stain, and merged images are shown at the far right for each time point.

significantly decreased in CCL2-deficient animals (43%
below wild-type; p < 0.001), which also resulted in a significant, 70% reduction in CD11b + monocytes expressing the CCL2 receptor CCR2+ (p < 0.0001; Figure 3B).
This previously reported monocytopenia in the blood of
CCL2-null mice [43] reflects the loss of the highly specific CCL2/CCR2-mediated release of monocytes, but not
neutrophils or lymphocytes, from the bone marrow of
these animals [44,45].
In response to the mild systemic hypoxia of HPC, the
peripheral distribution of leukocyte subsets was affected,
but in a predominantly CCL2-independent manner. Specifically, HPC reduced TCRb+ T lymphocyte and CD11b
+
monocyte populations in both CX3CR1GFP/+ wild type
(n = 6; p < 0.0001 for both subsets) and CCL2-null (n =
5; p < 0.001 for both subsets) mice. While these populations are significantly different in HPC-treated CCL2null mice compared to HPC-treated wild-types, the
magnitude of reduction for both TCRb+ T lymphocytes
(36% vs. 29%, respectively) and CD11b+ monocytes (82%
vs. 63%, respectively) was similar - a reflection of the
different baseline expression levels found in naïve animals and not an altered response to HPC in the absence
of CCL2. HPC induced a similar magnitude of downregulation of Gr1+ granulocytes in both wild-type mice
(47% reduction vs. naïve) and CCL2-null mice (44%

reduction vs. naïve), and again the response did not differ between genotypes. B lymphocytes increased in
response to HPC, with a 2.4-fold increase in
CX 3 CR1 GFP/+ wild-types (p < 0.0001) and a 1.8-fold
increase in CCL2-null mice (p < 0.0001) which, when
normalized to all CD45+ cells, was also unaffected by
the presence or absence of CCL2 (37% vs. 38%,
respectively).
CCL2 mediates the movement of CCR2+ monocytes from
blood following hypoxic preconditioning

The only CCL2-dependent effect of HPC on the distribution of leukocyte subsets related to CCR2+/CD11b+
monocytes. In wild-type mice, the 78% of monocytes
that express CCR2 under resting conditions was reduced
to 42% (p < 0.0001) following HPC, suggesting that
about half of the CCR2 + monocytes move out of the
peripheral circulation in response to HPC. Conversely,
in CCL2-null mice, HPC actually resulted in an increase
in the fraction of CCR2+ monocytes, from 23% to 49%
(p < 0.0001), although this may reflect the movement of
non-CCR2+ monocytes out of the blood of CCL2-null
mice, considering non-CCR2+ monocytes constitute 77%
of all monocytes in the knockouts. Coronal sections
from the brains of the same mice used for the flow cytometry studies described above show a similar and evenly
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Figure 3 HPC affects peripheral blood leukocyte populations. (A) Whole blood staining identified baseline difference for TCRb+ T
lymphocytes and CD11b+ monocytes in naïve (i.e., not exposed to hypoxia) CCL2 knockout (KO) mice versus naïve wild-type (WT) CX3CR1GFP/+
mice. HPC reduced Gr-1+ granulocytes, T lymphocytes, and monocytes, while increasing CD19+ B lymphocytes, to a similar extent in both
strains. Data are shown as the mean percent of CD45+ cells in the peripheral blood. (B) Representative staining for the chemokine receptor CCR2
on circulating monocytes showed significant strain differences at naïve levels that were equalized at 12 h after HPC. Whole blood was stained
and expression of CCR2 by CD45+CD11b+ monocytes was determined by comparison with monocytes stained with an isotype-matched control
antibody. (C, D, E) Representative cortical sections from animals in the above experiment display a similar distribution pattern and morphology
of resident CX3CR1-expressing monocytes/microglia at 12 h after HPC when seen at (D) 20 × and (E) 40 × magnification within the area
denoted by the white rectangle. (F) CCL2 staining in adjacent sections, denoted by the white squares in cortical and subcortical areas. *p < 0.05,
**p < 0.0001 vs. control.

distributed resident monocyte population in both wildtype and CCL2-null mice at 12 h after HPC (Figure 3CE). Given the well-known immune privilege of the CNS,
which serves to limit leukocyte extravasation from the
circulation into the brain under non-pathological conditions [25], we would contend that the mild hypoxic stimulus was not sufficient to increase monocyte
extravasation across an intact blood-brain barrier in
either wild-type or knockout mice. In fact, even during
an increase in monocyte recruitment into the brain
under bacterial pathogen-induced neuroinflammation,
CCL2 gene deletion did not affect extravasation [46],
due to either a CCR1-mediated chemotaxis [44,45,47],
or the expression of CCL7 and CCL12 in CCL2-null
mice [43]. Monocyte subpopulations extravasate into
mesentery, lung, and skeletal muscle in response to mild
hypoxia [48-50], which could account for their early
movement out of the circulation in our study; future
investigations should determine whether monocytes
enter the brain at any later post-hypoxic timepoints.

The delayed upregulation of CCL2 expression in cerebral endothelial cells 2 days after HPC would be consistent with such a possibility.
Hypoxic preconditioning does not provide tolerance to
transient focal stroke in CCL2-deficient mice

Because the neuronal upregulation of HIF-1 is neuroprotective [40], and to test our hypothesis that HPC
requires the HIF-mediated upregulation of neuronal
CCL2 to induce the protective phenotype, we examined
the ability of HPC to induce ischemic tolerance in
CCL2-null mice following transient focal stroke [4]. Figure 4A shows 24 h post-stroke infarct volumes for nonpreconditioned CCL2-null mice, and HPC-treated
CCL2-null mice in response to a 45-min tMCAo. In the
absence of CCL2, HPC exhibited no protective effect
with respect to infarct volume (114 ± 16 mm3; n = 5)
compared to non-preconditioned controls (114 ± 8
mm3; n = 6). These infarct volumes, however, are larger
than those reported in prior studies of CCL2-/- mice
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following a 30-min tMCAo [51], and following permanent MCAo [17]. While infarct volumes in the latter
study were similar to our previous experience with permanent MCAo [5], the smaller infarct volumes following
tMCAo that others reported may be due to the use of
different infarct quantification methods, as well as the
shorter 30-min duration of ischemia. Schilling and colleagues [51] stained intermittent coronal sections with
Toluidine Blue, and visually determined the infarct at
the time of sectioning - which may have resulted in the
exclusion of the most rostral and caudal portions of the
infarct that are included using our TTC quantification
protocol. We also examined another cohort of mice subjected to a 35-min tMCAo to ensure that the extent of
damage caused by a 45-min occlusion did not mask or
overwhelm any potential HPC-induced protection (Figure 4B). Again, HPC-treated CCL2-null mice had infarct
volumes (87 ± 10 mm3; n = 10) nearly identical to nonpreconditioned CCL2-nulls (91 ± 16 mm 3 ; n = 9).
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Taken together, the results from these two cohorts confirm our hypothesis that CCL2 is required for HPCinduced tolerance to transient focal stroke.
Finally, recent studies show conflicting roles for the
influence of CX 3 CR1 on the progression of ischemic
injury, with genetic deletion of either CX3CL1 (i.e., fractalkine) or CX 3 CR1 decreasing post-stroke ischemic
injury [52-54], whereas administration of CX 3 CL1 to
wild-type rodents, with intact immune systems, promoting neuroprotection and long-term behavioral recovery
[52]. Because our CCL2-null mice are on a CX3CR1GFP/
+
background, with one functional copy of the fractalkine receptor replaced by GFP in all CD11b+ monocytes
[55], we deemed it necessary to demonstrate that the
single-copy deletion of CX3CR1 in the CCL2-null mice
did not potentially mask cerebroprotection induced by
HPC. However, as shown in Figure 4C, we confirmed
that HPC prior to a 35-min tMCAo significantly
reduced infarct volumes in CX3CR1GFP/+ mice (32 ± 7
mm3; n = 5; p < 0.01) compared to non-preconditioned
controls (62 ± 6; n = 6), indicating that the single-copy
deletion of CX3CR1 had no effect on the ability of HPC
to promote stroke tolerance.
Immunoneutralization of CCL2 during hypoxic
preconditioning blocks neuroprotection

Figure 4 Genetic and pharmacologic evidence for CCL2
involvement in HPC-induced stroke tolerance. (A and B) HPCinduced ischemic tolerance was lacking in CCL2-null animals with
HPC completed 2 days prior to (A) a 45-min tMCAo (n = 6) or (B) a
35-min tMCAo (n = 9) tMCAo, versus control CCL2-null mice with
tMCAo but no prior HPC (n = 6 and n = 10, respectively). (C) HPC
promoted ischemic tolerance to a 35-min tMCAo in CX3CR1GFP/+
wild-type mice. (D) In WT mice, HPC 2 days prior to tMCAo (n = 12)
reduced infarct volume resulting from 45-min of tMCAo versus
controls with tMCAo but no prior HPC (n = 15).
Immunoneutralization of CCL2 prior to HPC reversed this protection
relative to untreated control mice with HPC (n = 9), and relative to
control mice given the IgG-isotype control antibody prior to HPC (n
= 11). Individual values (black-filled circles), mean (black horizontal
bars), 75% confidence interval (gray box), and values (open circles)
that fell outside of the 95% confidence interval (whiskers) are given.
*p < 0.05, **p < 0.0001 vs. HPC.

If the HPC-induced neuronal and/or cerebral endothelial production of CCL2 acts as part of an autocrine/
paracrine signaling mechanism, then preventing the
CCL2-induced activation of CCR2 receptors should also
inhibit HPC-induced tolerance in a manner similar to
the effects of CCL2 gene deletion. To test this hypothesis, we immunoneutralized CCL2 during HPC in wildtype mice using a dose of monoclonal, anti-CCL2 neutralizing antibody that was shown previously to reduce
infarct volumes in obese mice when administered intraperitoneally 3 h before stroke onset [28]. Figure 4D
depicts infarct volumes 24 h following tMCAo in nonpreconditioned mice, and in preconditioned mice with
and without the CCL2 neutralizing antibody. Note that,
in untreated mice, HPC reduced infarct volume by 27%
(75 ± 6 mm 3 ; n = 12 vs. 102 ± 6 mm 3 ; n = 15; p <
0.01). However, in mice receiving the antibody, the
development of HPC-induced tolerance was blocked,
resulting in infarct volumes (117 ± 5 mm3; n = 9; p =
0.16) significantly greater than HPC-treated mice with
control IgG antibody (87.4 mm3; n = 11; p < 0.01), and
15% greater than nonpreconditioned controls. Our
demonstration of the loss of the ischemia-tolerant phenotype by a CCL2-immunoneutralizing antibody, particularly when considered together with our
aforementioned results in CCL2-null mice, serves as
additional evidence implicating CCL2 in the HPCinduced triggering of the downstream signaling
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mechanisms that, in turn, are responsible for the
changes in gene expression required for HPC-induced
tolerance.
While our findings indicate that CCL2 is clearly
implicated in the establishment of HPC-induced neuroprotection, it is unclear whether neuronal CCL2
mRNA and protein upregulation, cerebral endothelial
cell CCL2 mRNA upregulation, and/or a peripheral
recruitment of CCR2-expressing monocytes by CCL2,
are required for triggering the genomic reprogramming
responsible for ischemic tolerance to stroke. Although
our findings implicate neurons as the predominant
source of early CCL2 protein within the cortex following HPC, our histological findings would suggest they
do not recruit from the circulation and into the CNS
significant numbers of CCR2-expressing monocytes at
the time of peak levels of CCL2 expression. In fact, in
addition to monocytes, HPC appears to drive several
leukocyte subpopulations out of the circulation, including granulocytes and T lymphocytes. Future flow cytometry experiments could determine (more definitively
than immunohistochemistry) if any of these leukocyte
subpopulations enter the CNS in response to HPC,
and over what time periods after HPC. Perhaps the
delayed upregulation of cerebral endothelial CCL2 that
we observed two days after HPC helps promote CCR2+
monocyte extravasation into the CNS at this later
time, given that CCL2 expression is required for
monocyte rolling and adherence to the venular
endothelium [34,35]. This HPC-induced, CCL2mediated recruitment of CCR2 + monocytes from the
periphery by cerebral endothelial cells would likely be
blocked by a systemically-delivered CCL2 immunoneutralizing antibody, which could have contributed to the
loss of HPC-induced stroke tolerance in mice receiving
such treatment. Currently, few studies suggest any protective roles for monocytes in stroke injury and repair
[56]. However, an elegant series of experiments following acute skeletal muscle injury show that CCL2 must
be expressed by all three compartments - bone marrow, monocytes, and the injured skeletal muscle - to
initiate phagocytosis of injured tissue and subsequent
regeneration [43]. Thus, it is not inconceivable that the
production of CCL2 from multiple cell types, and its
subsequent autocrine, paracrine, and chemotactic
actions, are needed to signal the induction of a pancellular ischemia-tolerant phenotype. A similar interplay between the neuronal-, endothelial-, and circulating immune cell-derived CCL2 and surrounding cells
may also be foundational to the protective effects of
“remote” preconditioning observed in both clinical and
preclinical studies [57-60].
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While hypoxia, via HIF-1, upregulates CCL2, it
would be of interest to determine if the genomic
reprogramming induced by other preconditioning stimuli also involves CCL2 signaling. Indeed, several
well-described preconditioning stimuli, including LPS,
TNF-a, interferon, and interleukin-1 beta (IL-1b),
upregulate CCL2 [15]. Moreover, overexpression of
CCL2 in cardiac myocytes mimics preconditioning
through the upregulation of the phosphorylated SAPK/
JNK1/2, but not ERK1/2 or p38, pathway [22], but
whether these or similar signaling intermediates are
involved in response to the more broad HPC stimulus
is not presently known. The autocrine actions of neuronal CCL2 could also modulate post-stroke plasticity
during recovery, given that exogenous CCL2 increases
firing rates and excitatory postsynaptic transmission in
CA1 hippocampal neurons [61], and/or influences neurotransmission - since CCR2 colocalizes with neurotransmitters in the cortex [62]. In addition to these
novel, plasticity-based, neuronal functions, the paracrine effects of neuron- and cerebral endothelial cellderived CCL2 on neighboring astrocytes, microglia,
and other cells within the CNS, and on circulating
immune cells, warrants further investigation.

Conclusions
Stroke affects over 800,000 individuals per year in the
United States, and although its rank as a cause of
death has fallen to fourth, it remains the primary contributor to long-term adult disability [63]. Every effort
should therefore be made to understand not only
stroke pathology, but also any endogenous mechanisms
that can be induced to establish a sustained ischemiatolerant phenotype. Over a decade ago, we reported
that a single exposure to systemic hypoxia, similar to
levels tolerated by humans [64,65], imparted a period
of tolerance to subsequent stroke injury [4]. In the
present investigation, we showed that the neuronal and
cerebral endothelial cell expression of CCL2 is upregulated in response to HPC. We also demonstrated a
concomitant, predominantly CCL2-independent alteration in circulating leukocyte subpopulations by HPC.
The spatio-temporal basis of these changes will require
further refinement, particularly with regard to the
potential for a delayed, endothelial cell-based, CCL2mediated recruitment of monocytes into the CNS.
Regardless, our findings that CCL2 gene deletion, or
its immunoneutralization during HPC, robustly
blocked HPC-induced stroke tolerance implicates
CCL2 in its induction. Thus, this work advances a fundamentally new role for CCL2: Initiating the host of
epigenetic changes in response to hypoxic
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preconditioning that ultimately establish a neurovascular-protective phenotype in the CNS.
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